Novimmune AG

Since our foundation, we have built a significant R&D pipeline of drug candidates, four of which are at various stages of clinical development. The most advanced of them, NI-0501, a fully human anti-IFN monoclonal antibody, has been granted Breakthrough therapy designation by the US Food and Drug Administration (FDA) and was also granted eligibility forPRIME (PRIority MEdicine) by the European Medicines Agency (EMA). The compound is in advanced phase 2/3 of clinical development to treat Hemophagocytic Lymphohistiocytosis (HLH), a life-threatening syndrome of extreme immune activation.